Sponsor Directory

AbbVie clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

816

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Follicular Lymphoma (FL)
Interventions: Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 58
States / cities: Fresno, California • San Diego, California • Santa Barbara, California + 48 more

Conditions: Ulcerative Colitis
Interventions: Risankizumab, Vedolizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more

Conditions: Healthy Volunteer
Interventions: ABBV-722, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 107
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more

Conditions: Healthy Volunteer
Interventions: ABBV-859, Placebo for ABBV-859; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 8
States / cities: Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Neuropathic Pain
Interventions: onabotulinum toxin A; Drug
Lead sponsor: Isabel Moreno Hay; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Virtual Reality; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography, Fludarabine, Granulocyte Colony-Stimulating Factor, Idarubicin, Multigated Acquisition Scan, Pivekimab Sunirine; Procedure · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression, Bipolar I Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 69
States / cities: Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more

Conditions: Healthy Volunteer
Interventions: ABBV-722, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Cypress, California • Grayslake, Illinois

About this AbbVie sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AbbVie is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AbbVie trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AbbVie clinical trials

Filter and sort this sponsor

Live official records

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Intraoral Administration of Botox in Patients With Dentoalveolar Neuropathic Pain

A Study of Virtual Reality and Linaclotide for IBS-C

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

About this AbbVie sponsor directory page